Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
May 31 2023 - 10:38AM
Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage
pharmaceutical company focused on the development and
commercialization of therapies for patients with rare genetic
mitochondrial diseases, today announced that the company’s
management team will participate at the Jefferies Healthcare
Conference.
Jefferies Healthcare ConferenceDate: Wednesday,
June 7, 2023Location: Marriott Marquis, New York, NYPresentation:
11:00 a.m. EDT (webcast)
Links to the webcast and presentation will be posted on
the Investors section of the Reneo Pharmaceuticals
corporate website.
About Reneo PharmaceuticalsReneo is a
clinical-stage pharmaceutical company focused on the development
and commercialization of therapies for patients with rare genetic
mitochondrial diseases, which are often associated with the
inability of mitochondria to produce adenosine triphosphate (ATP).
Our lead product candidate, mavodelpar (REN001), is a potent and
selective agonist of the peroxisome proliferator-activated receptor
delta (PPARδ). Mavodelpar has been shown to increase transcription
of genes involved in mitochondrial function, increase fatty acid
oxidation, and may increase production of new mitochondria. For
additional information, please see reneopharma.com.
Contacts:
Danielle Spangler Investor Relations Reneo
Pharmaceuticals, Inc. dspangler@reneopharma.com
David Melamed, Ph.D. Media Inquiries Russo Partners,
LLC david.melamed@russopartnersllc.com
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jul 2023 to Jul 2024